Impact of an angiotensin II receptor antagonist and antioxidant on count of stem cells and on morphofunctional parameters in animals
AbstractNow pathology of cardiovascular system is the major cause of cardiac morbidity and mortality in many countries. It is necessary to develop new methods of diagnosis and treatment of cardiovascular diseases. Studying new properties of drugs and substances to treat pathology of cardiovascular system is very important. Candesartan cilexetil is an angiotensin II receptor antagonist. This drug has a number of side effects. Resveratrol is the natural antioxidant, which has pleiotropic health beneficial effects. Effect of new combination of candesartan cilexetil with resveratrol on mobilization of stem cells was studied in the experiment. Goal. To investigate the effect of candesartan cilexetil and resveratrol at different doses on the number of stem cells, morphofunctional parameters in animals. Methods. Male Balb/C mice were used for the experiment. Animals were received intragastrically candesartan cilexetil and resveratrol at different doses for 7 weeks after physical strain. Evaluation of the effects of substances on mobilization of CD117+ stem cells from bone marrow to blood, morphofunctional parameters were detected by flow cytometry. Results. It was found that candesartan cilexetil at 3 mg/kg dose stimulated mobilization of CD117+ stem cells but was cytotoxic. Candesartan cilexetil at 1.5 mg/kg dose did not increased the number of CD117+ stem cells in bone marrow. The combination of candesartan cilexetil and resveratrol increased the amount of CD117+ stem cells in bone marrow and blood and was safe for cells. Conclusions. New combination of candesartan cilexetil and resveratrol was effective in increasing of the number of CD117+ stem cells and was safer than candesartan cilexetil alone.
2. De Rosa ML, Chiariello M. Candesartan improves maximal exercise capacity in hypertensives results of a randomized placebo-controlled crossover trial. J. Clin Hypertens. 2009; 11 (4): 192–200.
3. Adi Y. Berman, Rachel A. Motechin, Maia Y. Wiesenfeld, Marina K. Holz. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017; 1: 35.
4. Brisdelli F, D'Andrea G, Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr Drug Metab. 2009 Jul; 10(6): 530-46.
5. Riba A., Deres L., Sumegi B., Toth K., Szabados E., Halmosi R. Cardioprotective effect of resveratrol in a postinfarction heart failure model. Oxid. Med. Cell. Longev. 2017;2017:6819281. doi: 10.1155/2017/6819281.
6. Zhigang Zhang, Li Gao, Yanyan Cheng, Jing Jiang, Yan Chen, Huijie Jiang, Hongxiang Yu, Anshan Shan, Baojing Cheng. Resveratrol, a Natural Antioxidant, Has a Protective Effect on Liver Injury Induced by Inorganic Arsenic Exposure. BioMed Research International. Volume 2014, Article ID 617202, 7 pages. http://dx.doi.org/10.1155/2014/617202.
7. A. Shaito, A.M. Posadino, N. Younes, H. Hasan, S. Halabi,D. Alhababi, A. Al-Mohannadi, W. M Abdel-Rahman, A. H. Eid, G. K. Nasrallah, G. Pintus. Potential adverse effects of resveratrol: a literature review. Int. J. Mol. Sci. 2020; 21, 2084.
8. R. Habriyev. Guide to experimental (preclinical) studying new pharmacological substances. Medicine. 2005; 832 p.
9. Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Europ J of Pharmacology. 1998; 354 (2/3): 179–187.
10. G. Mantzios, S. Damianidou, L. Foudoulaki-Paparizos, A. Travlou, D. Kalantzis. A case of immune-mediated haemolytic anaemia probably associated to candesartan cilexetil/hydrochlorothiazide. Haema. 2006; 9 (4).
Abstract views: 2 PDF Downloads: 5